Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 297Lung Neoplasms 195Colorectal Neoplasms 54Small Cell Lung Carcinoma 52Neoplasms 39Ovarian Neoplasms 38Melanoma 37Pancreatic Neoplasms 33Breast Neoplasms 31Neoplasm Metastasis 27Stomach Neoplasms 26Squamous Cell Carcinoma of Head and Neck 24Carcinoma, Renal Cell 22Urinary Bladder Neoplasms 20Prostatic Neoplasms 20Esophageal Neoplasms 20Endometrial Neoplasms 20Head and Neck Neoplasms 19Triple Negative Breast Neoplasms 18Colonic Neoplasms 18Uterine Cervical Neoplasms 16Carcinoma, Hepatocellular 16Mesothelioma 15Lung Diseases 13Sarcoma 12Parkinson Disease 4, Autosomal Dominant Lewy Body 12Mesothelioma, Malignant 12Adenocarcinoma of Lung 11Cholangiocarcinoma 10Rectal Neoplasms 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous NSCLC × Thoracic × 30 days × Clear all
NCT07073183 2026-05-29

Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)

CureVac

Phase 1 Withdrawn
Thoracic

Squamous NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡